IG-001 (chemical polymer-bound nanoparticle paclitaxel) is a next generation paclitaxel formulation with clinical activity demonstrated to date to be at least on par with albumin-bound paclitaxel (Abraxane®). Clinical studies have shown that IG-001 has a higher maximum tolerated does (MTD) and a more gradual toxicity curve that allows for higher doses of paclitaxel. IG-001 also exhibits pharmacokinetic properties—including dose proportionality—
Clinical studies of IG-001 performed in the United States and other countries such as Korea and Russia, have demonstrated similar clinical activity as albumin-bound paclitaxel (Abraxane®) in patients with metastatic breast cancer, non-small cell lung cancer, advanced pancreatic cancer and ovarian cancer. IG-001 is currently approved and commercially available in Korea as Genexol PM®. These properties make IG-001 an ideal platform for personalized paclitaxel; where personalized dosing and patient selection are combined with the best paclitaxel nanoparticle formulation to potentially achieve safe and effective paclitaxel chemotherapy. “We, at IGDRASOL, are utilizing convergent technologies and our deep understanding of paclitaxel to deliver the next generation nanoparticle paclitaxel to the patients.” says Dr. Trieu.
About Biotech Showcase 2013:
Co-produced by Demy-Colton Life Science Advisors and EBD Group, Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies an opportunity to present to, and meet with, investors and pharmaceutical executives during the course of one of the industry’s largest annual healthcare investor conferences. Now in its fifth year, Biotech Showcase is expected to attract upwards of 1,500 attendees. The meeting will take place January 7-9, 2013 at the Parc 55 Wyndham San Francisco Union Square Hotel, California.
IGDRASOL is a developer of personalized nanoparticle paclitaxel therapy. At IGDRASOL, we are taking advantage of the convergence of technologies that make personalized paclitaxel therapy possible. Our platform is IG-001 (chemical polymer-bound nanoparticle paclitaxel), a next generation nanoparticle paclitaxel with clinical activity demonstrated to date to be at least on par with Abraxane. IG-001 is free of issues with Cremophor and albumin; excipients for Taxol® (Cremophor-based paclitaxel) and albumin-bound paclitaxel (Abraxane®), respectively. It combines the manufacturing simplicity of Taxol with the albumin-mediated transport properties of Abraxane. IGDRASOL will be conducting registration trials for multiple cancer indications.
IG-001(chemical polymer-bound nanoparticle paclitaxel) is approved in Korea and marketed by Samyang Biopharmaceuticals as Genexol-PM®. IGDRASOL, together with its corporate partners, are also developing quantitative point-of-care testing solutions for biomarker testing and paclitaxel therapeutic drug monitoring—technologies which would be instrumental in personalizing paclitaxel therapy. The executives of IGDRASOL are a group of pharmaceutical veterans who believe that personalized nanoparticle paclitaxel therapy will present a paradigm shift in the delivery of chemotherapeutic agents. To learn more about our mission please visit our website (http://www.igdrasol.com).
Genexol PM® is a registered trademark of Samyang Corporation. Abraxane® is a registered trademark of Celgene, Inc. Taxol® is a registered trademark of Bristol-Myers Squibb, Inc.
Vuong Trieu, Ph.D.
Chief Executive Officer
Forward-Looking Statements :
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statement that is not a statement of historical fact should be considered a forward-looking statement. These statements are based on management's current beliefs and expectations and our business is subject to numerous risks and uncertainties. Some of the risks include that we have a limited operating history and limited financial resources, that our product candidates have not completed clinical development and have not received and may not ever receive regulatory approval for commercialization. As a result of risks affecting our business, actual results or events could differ materially from the plans, projections and expectations set forth in our forward-looking statements, therefore, readers are cautioned not to place undue reliance on such forward-looking statements. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this presentation except as required by law.